$VXRT
Vaxart, Inc. Stock $vxrt

$vxrt Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000143774924016236 Filed on May 13, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2023 Q1
Revenue	$6.401M	$2.181M	$675.0K
YoY Change	371.35%	223.11%	694.12%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$5.177M	$7.238M	$6.625M
YoY Change	-7.52%	9.25%	-0.5%
% of Gross Profit
Research & Development	$17.48M	$19.01M	$19.62M
YoY Change	-7.09%	-3.1%	7.8%
% of Gross Profit
Depreciation & Amortization	$900.0K	$900.0K	$2.062M
YoY Change	-4.66%	-56.35%	457.3%
% of Gross Profit
Operating Expenses	$22.66M	$26.25M	$26.25M
YoY Change	-7.19%	0.02%	5.57%
Operating Profit	-$16.26M	-$24.07M	-$25.57M
YoY Change	-29.48%	-5.87%	3.21%
Interest Expense	$416.0K	$503.0K	$642.0K
YoY Change	-41.49%	-21.65%	1734.29%
% of Operating Profit
Other Income/Expense, Net			-$178.0K
YoY Change			-47.65%
Pretax Income	-$16.45M	-$24.37M	-$25.11M
YoY Change	-27.01%	-2.94%	0.12%
Income Tax	$21.00K	$45.00K	$29.00K
% Of Pretax Income
Net Earnings	-$16.47M	-$24.42M	-$25.14M
YoY Change	-26.98%	-2.88%	0.16%
Net Earnings / Revenue	-257.24%	-1119.53%	-3724.44%
Basic Earnings Per Share	-$0.09	-$0.14	-$0.19
Diluted Earnings Per Share	-$0.09	-$0.14	-$0.19
COMMON SHARES
Basic Shares Outstanding	176.8M	173.9M	135.6M
Diluted Shares Outstanding

Balance Sheet

Concept	2024 Q2	2024 Q1	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$62.59M	$36.66M	$71.81M
YoY Change	-7.82%	-48.94%	-51.37%
Cash & Equivalents	$43.29M	$26.74M	$48.40M
Short-Term Investments	$19.31M	$14.88M	$23.38M
Other Short-Term Assets	$328.0K	$2.105M	$3.755M
YoY Change	-90.14%	-43.94%	-41.7%
Inventory
Prepaid Expenses
Receivables	$1.088M	$556.0K	$264.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$71.54M	$44.28M	$75.83M
YoY Change	0.38%	-41.6%	-50.82%
LONG-TERM ASSETS
Property, Plant & Equipment	$10.28M	$11.10M	$14.37M
YoY Change	-26.14%	-22.76%	88.4%
Goodwill	$4.508M	$4.508M	$4.508M
YoY Change	0.0%	0.0%	0.18%
Intangibles	$3.923M	$4.106M	$4.837M
YoY Change	-15.71%	-15.11%	-52.97%
Long-Term Investments
YoY Change
Other Assets	$851.0K	$917.0K	$2.460M
YoY Change	-43.57%	-62.72%	58.1%
Total Long-Term Assets	$42.21M	$44.39M	$54.02M
YoY Change	-17.86%	-17.84%	16.93%
TOTAL ASSETS
Total Short-Term Assets	$71.54M	$44.28M	$75.83M
Total Long-Term Assets	$42.21M	$44.39M	$54.02M
Total Assets	$113.7M	$88.67M	$129.9M
YoY Change	-7.26%	-31.71%	-35.2%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.587M	$3.978M	$3.882M
YoY Change	-14.57%	2.47%	-3.36%
Accrued Expenses	$6.611M	$4.980M	$6.977M
YoY Change	9.27%	-28.62%	36.72%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$2.686M	$2.360M	$900.0K
YoY Change	198.44%	162.22%	12.5%
Total Short-Term Liabilities	$15.76M	$14.12M	$15.68M
YoY Change	13.49%	-9.99%	42.12%
LONG-TERM LIABILITIES
Long-Term Debt	$1.591M	$1.863M	$0.00
YoY Change
Other Long-Term Liabilities	$405.0K	$309.0K	$246.0K
YoY Change	54.58%	25.61%	32.26%
Total Long-Term Liabilities	$405.0K	$309.0K	$246.0K
YoY Change	54.58%	25.61%	32.26%
TOTAL LIABILITIES
Total Short-Term Liabilities	$15.76M	$14.12M	$15.68M
Total Long-Term Liabilities	$405.0K	$309.0K	$246.0K
Total Liabilities	$33.74M	$32.98M	$40.10M
YoY Change	-10.23%	-17.75%	17.89%
SHAREHOLDERS EQUITY
Retained Earnings	-$450.5M	-$434.0M	-$352.2M
YoY Change	20.19%	23.21%	44.1%
Common Stock	$531.1M	$490.2M	$442.1M
YoY Change	15.46%	10.89%	7.53%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$80.01M	$55.69M	$89.75M
YoY Change
Total Liabilities & Shareholders Equity	$113.7M	$88.67M	$129.9M
YoY Change	-7.26%	-31.71%	-35.2%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2023 Q1
OPERATING ACTIVITIES
Net Income	-$16.47M	-$24.42M	-$25.14M
YoY Change	-26.98%	-2.88%	0.16%
Depreciation, Depletion And Amortization	$900.0K	$900.0K	$2.062M
YoY Change	-4.66%	-56.35%	457.3%
Cash From Operating Activities	-$12.03M	-$21.19M	-$24.46M
YoY Change	-31.16%	-13.36%	-2.6%
INVESTING ACTIVITIES
Capital Expenditures	$370.0K	$131.0K	$1.239M
YoY Change	-18.5%	-89.43%	-7.95%
Acquisitions
YoY Change
Other Investing Activities	-$9.294M	-$4.893M	$26.70M
YoY Change	723.21%	-118.33%	425.8%
Cash From Investing Activities	-$9.664M	-$5.024M	$25.46M
YoY Change	510.49%	-119.73%	582.23%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	38.24M	$18.20M	$1.420M
YoY Change	175.17%	1181.34%	36.54%
NET CHANGE
Cash From Operating Activities	-12.03M	-$21.19M	-$24.46M
Cash From Investing Activities	-9.664M	-$5.024M	$25.46M
Cash From Financing Activities	38.24M	$18.20M	$1.420M
Net Change In Cash	16.55M	-$8.020M	$2.421M
YoY Change	-420.92%	-431.27%	-111.9%
FREE CASH FLOW
Cash From Operating Activities	-$12.03M	-$21.19M	-$24.46M
Capital Expenditures	$370.0K	$131.0K	$1.239M
Free Cash Flow	-$12.40M	-$21.32M	-$25.70M
YoY Change	-30.84%	-17.03%	-2.87%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	dei	Amendment Flag AmendmentFlag	false
CY2024Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2024Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	177187965
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	176523042
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	153959853
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	153452833
CY2024Q1	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	664923
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	507020
CY2024Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	pure
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	usd
CY2023Q1	us-gaap	Depreciation Depreciation	900000	usd
CY2023Q1	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	0	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	200000	usd
CY2024Q1	us-gaap	Goodwill Goodwill	4500000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	4500000	usd
CY2024Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q1	dei	Document Type DocumentType	10-Q
CY2024Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2024Q1	dei	Document Period End Date DocumentPeriodEndDate	2024-03-31
CY2024Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2024Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2024Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	South San Francisco
CY2024Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2024Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94080
CY2024Q1	dei	City Area Code CityAreaCode	650
CY2024Q1	dei	Local Phone Number LocalPhoneNumber	550-3500
CY2024Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value
CY2024Q1	dei	Trading Symbol TradingSymbol	VXRT
CY2024Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2024Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024Q1	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	176838011
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	26735000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	34755000	usd
CY2024Q1	us-gaap	Short Term Investments ShortTermInvestments	9929000	usd
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	4958000	usd
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	556000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3008000	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7064000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2815000	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	44284000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	45536000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11102000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11731000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	23753000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	24840000	usd
CY2024Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	4106000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	4289000	usd
CY2024Q1	us-gaap	Goodwill Goodwill	4508000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	4508000	usd
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	917000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	926000	usd
CY2024Q1	us-gaap	Assets Assets	88670000	usd
CY2023Q4	us-gaap	Assets Assets	91830000	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	3978000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1584000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4980000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5634000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2799000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2703000	usd
CY2024Q1	vxrt	Liability Related To Sale Of Future Royalties Current LiabilityRelatedToSaleOfFutureRoyaltiesCurrent	2360000	usd
CY2023Q4	vxrt	Liability Related To Sale Of Future Royalties Current LiabilityRelatedToSaleOfFutureRoyaltiesCurrent	3803000	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	14117000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13724000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	16691000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	17385000	usd
CY2024Q1	vxrt	Liability Related To Sale Of Future Royalties Noncurrent LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent	1863000	usd
CY2023Q4	vxrt	Liability Related To Sale Of Future Royalties Noncurrent LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent	2623000	usd
CY2024Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	309000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	293000	usd
CY2024Q1	us-gaap	Liabilities Liabilities	32980000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	34025000	usd
CY2024Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	18000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	15000	usd
CY2024Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	490221000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	467731000	usd
CY2024Q1	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	548000	usd
CY2023Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	366000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-433991000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-409574000	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-10000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	55690000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	57805000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	88670000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	91830000	usd
CY2024Q1	us-gaap	Revenues Revenues	2181000	usd
CY2023Q1	us-gaap	Revenues Revenues	675000	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19013000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19622000	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7238000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6625000	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	26251000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	26247000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-24070000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-25572000	usd
CY2024Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	503000	usd
CY2023Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	642000	usd
CY2024Q1	vxrt	Noncash Interest Expense On Liability NoncashInterestExpenseOnLiability	804000	usd
CY2023Q1	vxrt	Noncash Interest Expense On Liability NoncashInterestExpenseOnLiability	178000	usd
CY2024Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-1000	usd
CY2023Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-3000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-24372000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-25111000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	45000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	29000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-24417000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-25140000	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.14
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.19
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	168811095
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	135213196
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-24417000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-25140000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-9000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	229000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-24426000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-24911000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	57805000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	7000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
CY2024Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	182000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4116000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-9000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-24417000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	55690000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	110597000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
CY2023Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	10000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2647000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	229000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-25140000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	89753000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-24417000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-25140000	usd
CY2024Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2177000	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2062000	usd
CY2024Q1	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	87000	usd
CY2023Q1	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	144000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	4116000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2647000	usd
CY2024Q1	vxrt	Noncash Interest Expense On Liability NoncashInterestExpenseOnLiability	804000	usd
CY2023Q1	vxrt	Noncash Interest Expense On Liability NoncashInterestExpenseOnLiability	178000	usd
CY2024Q1	vxrt	Noncash Revenue Related To Sale Of Future Royalties NoncashRevenueRelatedToSaleOfFutureRoyalties	3007000	usd
CY2023Q1	vxrt	Noncash Revenue Related To Sale Of Future Royalties NoncashRevenueRelatedToSaleOfFutureRoyalties	20000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2452000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	244000	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	4240000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1067000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2314000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-270000	usd
CY2024Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	usd
CY2023Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-397000	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1303000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-4199000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-21191000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-24460000	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	131000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1239000	usd
CY2024Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	9893000	usd
CY2023Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	-0	usd
CY2024Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	5000000	usd
CY2023Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	26700000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5024000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	25461000	usd
CY2024Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	7000	usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
CY2024Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	182000	usd
CY2023Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	10000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	18195000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1420000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-8020000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	2421000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	34755000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	46013000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	26735000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	48434000	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26735000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	46831000	usd
CY2024Q1	us-gaap	Restricted Cash RestrictedCash	0	usd
CY2023Q1	us-gaap	Restricted Cash RestrictedCash	1603000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	26735000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	48434000	usd
CY2024Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2023Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	296000	usd
CY2024Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	151000	usd
CY2023Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	246000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	36700000	usd
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt;"><b>Use of Estimates</b> – The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and disclosure of contingent assets and liabilities in the financial statements and accompanying notes. Actual results and outcomes could differ from these estimates and assumptions.</p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt;"> </p>
CY2024Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt;"><b>Concentration of Credit Risk</b> – Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash, cash equivalents, available-for-sale investments and accounts receivable. The Company places its cash, cash equivalents and available-for-sale investments at financial institutions that management believes are of high credit quality. The Company is exposed to credit risk in the event of default by the financial institutions holding the cash and cash equivalents to the extent such amounts are in excess of the federally insured limits. Losses incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations, and cash flows.</p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt;"> </p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt;">The primary focus of the Company’s investment strategy is to preserve capital and meet liquidity requirements. The Company’s investment policy addresses the level of credit exposure by limiting the concentration in any <em style="font: inherit;">one</em> corporate issuer or sector and establishing a minimum allowable credit rating.</p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt;"> </p>
CY2024Q1	us-gaap	Investments And Cash InvestmentsAndCash	36674000	usd
CY2024Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	10000	usd
CY2024Q1	vxrt	Investments And Cash Fair Value Disclosure InvestmentsAndCashFairValueDisclosure	36664000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	26735000	usd
CY2024Q1	us-gaap	Short Term Investments ShortTermInvestments	9929000	usd
CY2023Q4	us-gaap	Investments And Cash InvestmentsAndCash	39714000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1000	usd
CY2023Q4	vxrt	Investments And Cash Fair Value Disclosure InvestmentsAndCashFairValueDisclosure	39713000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	34755000	usd
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	4958000	usd
CY2024Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	usd
CY2024Q1	vxrt	Prepaid Clinical And Manufacturing Expenses PrepaidClinicalAndManufacturingExpenses	1762000	usd
CY2023Q4	vxrt	Prepaid Clinical And Manufacturing Expenses PrepaidClinicalAndManufacturingExpenses	984000	usd
CY2024Q1	us-gaap	Government Contract Receivable Unbilled Amounts GovernmentContractReceivableUnbilledAmounts	1596000	usd
CY2023Q4	us-gaap	Government Contract Receivable Unbilled Amounts GovernmentContractReceivableUnbilledAmounts	0	usd
CY2024Q1	us-gaap	Prepaid Insurance PrepaidInsurance	933000	usd
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	258000	usd
CY2024Q1	us-gaap	Prepaid Rent PrepaidRent	528000	usd
CY2023Q4	us-gaap	Prepaid Rent PrepaidRent	488000	usd
CY2024Q1	us-gaap	Interest Receivable Current InterestReceivableCurrent	140000	usd
CY2023Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	127000	usd
CY2024Q1	us-gaap	Other Assets Current OtherAssetsCurrent	2105000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	958000	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7064000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2815000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	18562000	usd
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7734000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6831000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	18836000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11102000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11731000	usd
CY2024Q1	us-gaap	Depreciation Depreciation	900000	usd
CY2024Q1	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	0	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	23800000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	24800000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	5080000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	5080000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	974000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	791000	usd
CY2024Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	4106000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	4289000	usd
CY2024Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	200000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	548000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	732000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	731000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	731000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	727000	usd
CY2024Q1	vxrt	Finitelived Intangible Asset Expected Amortization After Year Four FinitelivedIntangibleAssetExpectedAmortizationAfterYearFour	637000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	4106000	usd
CY2024Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3199000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4576000	usd
CY2024Q1	vxrt	Accrued Clinical And Manufacturing Expenses Current AccruedClinicalAndManufacturingExpensesCurrent	180000	usd
CY2023Q4	vxrt	Accrued Clinical And Manufacturing Expenses Current AccruedClinicalAndManufacturingExpensesCurrent	312000	usd
CY2024Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	707000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	211000	usd
CY2024Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	894000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	535000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4980000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5634000	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2000000	usd
CY2024Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.098	pure
CY2024Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y10M24D
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	3306000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	4511000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	5031000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	5207000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	5389000	usd
CY2024Q1	vxrt	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	1348000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	24792000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	5302000	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	19490000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2799000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	16691000	usd
CY2024Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	1554000	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	1510000	usd
CY2024Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	12000	usd
CY2023Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	21000	usd
CY2024Q1	us-gaap	Variable Lease Cost VariableLeaseCost	504000	usd
CY2023Q1	us-gaap	Variable Lease Cost VariableLeaseCost	511000	usd
CY2024Q1	us-gaap	Sublease Income SubleaseIncome	14000	usd
CY2023Q1	us-gaap	Sublease Income SubleaseIncome	-0	usd
CY2024Q1	us-gaap	Lease Cost LeaseCost	2056000	usd
CY2023Q1	us-gaap	Lease Cost LeaseCost	2042000	usd
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q3	vxrt	Common Stock Increase In Shares Authorized CommonStockIncreaseInSharesAuthorized	100000000
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2024Q1	us-gaap	Dividends Dividends	0	usd
CY2024Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	29588664
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	27043664
CY2024Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	211259
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	5685806
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	17938726
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.9
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	3000000
CY2024Q1	vxrt	Share Based Compensation Arrangement By Share Based Payment Award Shares Available For Grant Decrease From Grants ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantDecreaseFromGrants	6555730
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	4734937
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.16
CY2024Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	8865
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.78
CY2024Q1	vxrt	Sharebased Compensation Arrangement By Sharebased Payment Award Nonoption Equity Instruments Released SharebasedCompensationArrangementBySharebasedPaymentAwardNonoptionEquityInstrumentsReleased	429960
CY2024Q1	vxrt	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Released Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedWeightedAverageGrantDateFairValue	1.27
CY2024Q1	vxrt	Share Based Compensation Arrangement By Share Based Payment Award Forfeited ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeited	981822
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	778613
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	2.4
CY2024Q1	vxrt	Share Based Compensation Arrangement By Share Based Payment Award Canceled ShareBasedCompensationArrangementByShareBasedPaymentAwardCanceled	42619
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	42619
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	3.35
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	3154517
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	21843566
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.54
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	21843566
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.54
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y6M29D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	4400000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	11444731
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	3.02
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y1M24D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	2200000	usd
CY2024Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	7000	usd
CY2024Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	8865
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	3000	usd
CY2023Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2024Q1	us-gaap	Share Price SharePrice	1.3
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.04
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.78
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4116000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2647000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-24417000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-25140000	usd
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	168811095
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	135213196
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.14
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.19
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	20694388
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16315008

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0001437749-24-016236-index-headers.html	Edgar Link	pending
0001437749-24-016236-index.html	Edgar Link	pending
0001437749-24-016236.txt	Edgar Link	pending
0001437749-24-016236-xbrl.zip	Edgar Link	pending
a01.jpg	Edgar Link	pending
ex_634995.htm	Edgar Link	pending
ex_634996.htm	Edgar Link	pending
ex_634997.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
vxrt-20240331.xsd	Edgar Link	pending
vxrt20240331_10q.htm	Edgar Link	pending
vxrt-20240331_cal.xml	Edgar Link	unprocessable
vxrt-20240331_def.xml	Edgar Link	unprocessable
vxrt-20240331_pre.xml	Edgar Link	unprocessable
vxrt-20240331_lab.xml	Edgar Link	unprocessable
vxrt20240331_10q_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VXRT
Vaxart, Inc. Stock $vxrt

2024 Q2 Form 10-Q Financial Statement

#000143774924016236 Filed on May 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VXRT Vaxart, Inc. Stock $vxrt

2024 Q2 Form 10-Q Financial Statement

#000143774924016236 Filed on May 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VXRT
Vaxart, Inc. Stock $vxrt